Vanguard Total International Stock ETF

Most Recent

  • uploads///CP Carloads Intemodal
    Industrials

    Why Canadian Pacific Railway’s Freight Growth Slowed

    Canadian Pacific Railway reported a railcar volume loss of 1% YoY in the 28th week of 2017 (ended July 15). The company moved ~30,000 railcars that week.

    By Samuel Prince
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s New Oncology Portfolio May See Healthy Growth

    In 1Q17, AstraZeneca’s (AZN) new oncology portfolio reported global sales of around $236.0 million. Tagrisso earned revenues of $171.0 million globally.

    By Margaret Patrick
  • uploads///brexit dev vs emerging
    Financials

    Investors Shift Their Focus to the UK—What Lies Ahead?

    In this series, we’ll look at some asset managers’ perspectives on the Brexit vote and its effect on the Market. We’ll identify factors that could lead to similar votes, and we’ll discuss what lies ahead for the UK.

    By Surbhi Jain
  • uploads///Graph
    Company & Industry Overviews

    Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017

    On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).

    By Margaret Patrick
  • uploads///Major Indexes Recovered Impressively Post Brexit Fall
    Fund Managers

    Why Investors Shouldn’t Be Panicked about Brexit

    All the global markets recovered impressively after their two-day falls as a result of the Brexit results.

    By Sarah Sands
  • uploads///Graph
    Company & Industry Overviews

    Novartis Focuses on Portfolio Prioritization to Boost Profitability

    To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017

    Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.

    By Margaret Patrick
  • uploads///effect on GDP
    Financials

    How Brexit Could Impact GDP, Capital Flows, and Growth in the UK

    According to the International Monetary Fund’s World Economic Outlook Database, the UK’s GDP was $2.7 trillion in 2015.

    By Surbhi Jain
  • uploads///CP Carloads
    Miscellaneous

    What Led to Canadian Pacific Railway’s Volume Rise in Week 30?

    CP hauled slightly more than 30,000 railcars in the 30th week compared with over 29,000 railcars in the 30th week last year.

    By Samuel Prince
  • Financials

    Must-know: Why junk bond spreads react to market momentum

    High yield debt mutual funds recorded a net inflow of $1.7 billion in the week ending October 24.

    By Phalguni Soni
  • Financials

    Why some unconstrained bond funds are seeing investor outflows

    Legendary bond investor Bill Gross left Pacific Investment Management Co. (or PIMCO) in September, causing investors to exit en masse from PIMCO-sponsored funds. Total outflows for all of PIMCO’s funds were estimated at $23.5 billion in September.

    By Phalguni Soni
  • uploads///repricing
    Financials

    Everything Is Being Repriced after the Brexit Vote, Says Marc Lasry

    The Brexit referendum results are already playing havoc with the European and other world capital markets.

    By Surbhi Jain
  • uploads///eu members disintegrating
    Financials

    George Soros: Brexit May Spark Disintegration in the European Union

    With the Brexit vote, the European Union’s disintegration has already begun. The pound is already at historic lows against the US dollar (UUP).

    By Surbhi Jain
  • uploads///median age
    Financials

    Bill Gross: What’s His New Normal Thesis?

    Recently, Gross has been repeatedly mentioning a “new normal” that the developed world seems to be in. Real GDP growth is around 2% in the US.

    By Surbhi Jain
  • uploads///dual mandate
    Financials

    Bill Gross: Possibility of Deglobalization in the Economy

    Gross warned about deglobalization in the global economy. Trade between nations, exacerbating immigration issues, and stagnant economic growth formed his belief.

    By Surbhi Jain
  • uploads/// Global growth
    Miscellaneous

    Why Investors Should Monitor Geopolitical Risks

    Localized geopolitical risks like the tension in the Middle East are unlikely to cause substantial damage to the markets in the long run, though they could bolster oil prices in the short term.

    By Peter Barnes
  • uploads///VRX revenue
    Company & Industry Overviews

    A Deeper Look at Valeant Pharmaceuticals’ Recent Financial Performance

    In 3Q16, Valeant Pharmaceuticals (VRX) generated revenues of $2.4 billion, compared with $2.2 billion in 3Q17.

    By Kenneth Smith
  • uploads///
    Macroeconomic Analysis

    What’s behind the Stock Market Fall?

    A fall of more than 10% in market value from the most recent peak is generally considered to be a correction. The US indexes have had four such corrections since the onset of the current bull market cycle in 2009.

    By Ricky Cove
  • uploads///Chart  Ratings
    Earnings Report

    Analysts’ Recommendations for Novartis after Its 4Q17 Earnings

    Novartis (NVS) is expected to report earnings per share of $1.26 in 1Q18 compared to EPS of $1.13 in 1Q17.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    GlaxoSmithKline Projects Tough Environment for Triumeq and Tivicay

    In 3Q17, dolutegravir franchise drugs Triumeq and Tivicay were major drivers of GlaxoSmithKline’s (GSK) rising HIV portfolio revenues.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for GlaxoSmithKline in January 2018

    Of the 31 analysts covering GlaxoSmithKline in January 2018, five have recommended a “strong buy,” seven have recommended a “buy,” 15 have recommended a “hold,” three have recommended a “sell,” and only one has recommended a “strong sell.”

    By Margaret Patrick
  • uploads///Kymriah
    Company & Industry Overviews

    How Is Novartis’s Kymriah Positioned for 2018?

    FDA and EC approvals for label expansion are expected to further boost Kymriah’s sales growth.

    By Daniel Collins
  • uploads///key focus areas
    Company & Industry Overviews

    Teva Pharmaceutical: Still Focused on New Product Launches

    With the acquisition of Actavis, Teva has a combination of the biggest first-to-file generics and biosimilars portfolio in the United States.

    By Sarah Collins
  • uploads///financial profile
    Company & Industry Overviews

    How Teva Pharmaceutical Plans to Improve Financial Profile

    Teva Pharmaceutical has implemented a clear strategy to improve its financial profile and establish long-term growth prospects.

    By Sarah Collins
  • uploads///Iressa
    Company & Industry Overviews

    A Look at AstraZeneca’s Iressa, Zoladex, Casodex, and Arimidex

    In 3Q17, AstraZeneca’s (AZN) Iressa generated revenues of $137.0 million, which reflected ~10.0% growth on a year-over-year basis.

    By Daniel Collins
  • uploads///Gilenya
    Company & Industry Overviews

    Behind Novartis’s Entresto and Gilenya Performances in 3Q17

    In 3Q17, Novartis’s (NVS) Entresto generated revenues of $128 million, compared with $53 million in 3Q16. Entresto witnessed a ~16% rise on a QoQ basis.

    By Daniel Collins
  • uploads///Immunology
    Company & Industry Overviews

    How Novartis’s Immunology and Dermatology Portfolio Looks after 3Q17

    In 3Q17, Novartis’s (NVS) Neoral generated revenues of ~$126 million, which represents a ~3% YoY (year-over-year) fall and a 2% QoQ fall.

    By Daniel Collins
  • uploads///Siliq
    Company & Industry Overviews

    Siliq Could Strengthen Valeant’s Dermatology Franchise

    In October 2017, Valeant Pharmaceuticals presented the results of its pivotal Phase 3 long-term extension AMAGINE-2 trial with Siliq.

    By Daniel Collins
  • uploads///Tecentriq trial
    Company & Industry Overviews

    Could Tecentriq Be Roche’s Long-Term Growth Driver?

    In July 2017, the EC’s CHMP recommended a positive opinion for Roche’s (RHHBY) Tecentriq as a monotherapy for the treatment of adults with metastatic NSCLC previously treated with chemotherapy.

    By Daniel Collins
  • uploads///Gleevec tasigna
    Company & Industry Overviews

    How Are Novartis’s Blockbuster Drugs Gleevec and Tasigna Positioned?

    In 1H17, Novartis’s (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Chart  Con
    Company & Industry Overviews

    GlaxoSmithKline’s Consumer Healthcare Business Improved

    GlaxoSmithKline (GSK) added new products and improved the supply chain for consumer healthcare products in the last few years.

    By Mike Benson
  • uploads///CNI Carloads
    Industrials

    Canadian Pacific Railway’s Freight Traffic Was a Mixed Bag in Week 32

    Canadian Pacific Railway (CP) is the second largest freight rail in Canada.

    By Samuel Prince
  • uploads///Graph
    Company & Industry Overviews

    EMEA and APAC: Fresenius Medical Care’s Dialysis Products Business

    In 1H17, Fresenius Medical Care (FMS) earned ~1.6 billion euros from the sale of dialysis products, which equals year-over-year growth of 8% on a reported basis.

    By Margaret Patrick
  • uploads///Chart  Resp
    Company & Industry Overviews

    Examining the 1Q17 Performance of AZN’s Respiratory Segment

    AstraZeneca’s (AZN) Respiratory segment is one its key growth platforms. The segment reported nearly flat revenue of $1.2 billion at constant exchange rates in 1Q17.

    By Mike Benson
  • uploads///Increasing Level of Private Sector Debt in China
    Macroeconomic Analysis

    Will There Be an Economic Slowdown in 2017?

    Any slowdown in China’s economic growth is expected to impact developed (SPY) (EWU) (HEDJ) and emerging economies (FXI) (EEM).

    By Mary Sadler
  • uploads///Graph
    Miscellaneous

    Does Novartis See Much Potential for Its Surgical Business?

    In 2017, Novartis (NVS) has planned to conduct a review of its Alcon segment to evaluate the business’s growth potential.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novartis Has Revamped Its Commercial Strategy for 2017

    Besides focusing on research and development (or R&D) efforts, Novartis (NVS) is also aiming to revamp its commercial strategy in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Novartis Is Aiming to Increase Entresto Sales in 2017

    In 2017, Novartis (NVS) expects its heart failure drug, Entresto, to earn revenues in excess of $500 million.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Novartis in 2017

    In 2016, Novartis (NVS) reported revenues of $48.4 billion, a flat year-over-year (or YoY) performance on a constant currency basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s Symbicort: Dominant Player in Inhaler Segment

    In 2016, AstraZeneca’s (AZN) Symbicort reported revenues close to $3.0 billion, which is a YoY fall of about 10.0% on a CER basis.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Changes in AstraZeneca’s Valuation in Fiscal 2016

    AstraZeneca (AZN) reported an ~5% decline in its fiscal 2016 revenues at constant exchange rates. It reported revenues of $23.0 billion, compared to ~$23.6 billion in fiscal 2015.

    By Mike Benson
  • uploads///Upward Revision in Growth Outlook For  Post Brexit
    Company & Industry Overviews

    What Impact Did the Brexit Vote Have on the UK and Global Growth?

    In an interview with Wall Street Week on February 10, 2017, Bob Diamond spoke about the impact of Brexit on global growth and the European markets.

    By Mary Sadler
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Revenue Trend for 4Q16

    On February 8, 2017, GlaxoSmithKline (GSK) reported its 4Q16 earnings. Revenues rose 21.0% to 7.6 billion pounds, and EPS was 26 pence.

    By Mike Benson
  • uploads///Weak Global Trade Continues To Affect the Global Growth
    Company & Industry Overviews

    Fiscal and Trade Policies to Work Closely for Economic Growth

    The Trump administration’s protectionist policy decisions are expected to affect global trade.

    By Mary Sadler
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s Tagrisso Had a Strong Commercial Launch in 2016

    After its commercial launch in 41 countries, AstraZeneca’s Tagrisso has witnessed a solid uptake, earning revenues of $276.0 million in 2016 YTD.

    By Margaret Patrick
  • uploads/// Shanghai Stock
    Company & Industry Overviews

    Why China Could Surprise Markets to the Upside

    The massive financial stimulus package unleashed in China (MCHI) appears to be supporting economic growth in 2016 and 2017.

    By Aberdeen Closed-End Funds
  • uploads///A China PLR
    Company & Industry Overviews

    China’s Unleashing a Massive Stimulus to Boost the Economy

    China’s (FXI) (MCHI) government initiated various stimulus measures to arrest the slowing growth. Currently, the bank lending rate is at a record low.

    By Aberdeen Closed-End Funds
  • uploads///Dry bulk industry Intro
    Macroeconomic Analysis

    Dry Bulk Shipping Industry: Performance in 2015

    Dry bulk shipping got a major boost from China’s increased appetite for iron ore and coal almost eight years ago. Large ship orders are driving the current oversupply.

    By Anuradha Garg
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.